Two independent organoid lines were tested, C001 and C002, both are KRAS WT, both express high levels of RAC1B compared to the stage 3 invasive tumour utilised above (Fig. S7F) and both show resistance to cetuximab treatment in vitro. The gene discussed is KRAS; the disease is neoplasm.